Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Given the substitution rates documented in independent testing, that reliance is not advisable
Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Stat2-Drp1 mediated mitochondrial mass increase is necessary for pro-inflammatory differentiation of macrophages
Research shows that up to 39% of weight lost on semaglutide can be lean body mass, compared to 20-30% with diet and exercise alone
US$ 26.29
US$ 21.32
US$ 27.50
US$ 24.58
US$ 21.55
US$ 27.62
